Metabolic Diseases

Binge Eating : The most common eating disorder worldwide

Binge-eating disorder (BED) is a severe, life-threatening, and treatable eating disorder characterized by recurrent episodes of eating large quantities of food (often very quickly and to the point of discomfort); a feeling of a loss of control during the binge; experiencing shame, distress or guilt afterwards; and not regularly using unhealthy compensatory measures (e.g., purging) to counter the binge eating. BED is the most common eating disorder worldwide, affecting between 1.92 and 4.45% of young female depending on the country/continent studied. However, to date, and despite the high medical need, Lisdexamfetamine is the only approved therapy for BED.

of people affected 
worldwide

> 0 MM

Global Health costs
for Binge-eating

> 0 bn

pharmacological  
treatment to date

Models

We have developed and extensively characterized an intermittent access model of binge eating in female rat for chronic efficacy and MoA studies of compounds aiming BED. The model rapidly develops intermittent hyperphagia episodes that can be fully reverse with sibutramine and topiramate.

Nutritional models

Rat intermittent access model of binge eating.

Methods

We master gold-standard methods to provide you with high-added value data about your health products efficacy and mechanisms of action on key hallmarks of BED such as food intake, body weight, circulating plasma biomarkers. In addition, we offer complementary techniques that allow performing histological and genomic analyses on key tissues and organs.